MMF Similar to Conventional Therapies for MN, FSGS
A six-month course of treatment with mycophenolate mofetil (MMF) is as effective as conventional therapies for treating membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), according to a pilot study conducted in India.
A team at the Postgraduate Institute of Medical Education and Research in
The proportion of patients achieving remission was similar in group A and group B (64% and 80% in MN patients and 70% and 69% in FSGS patients, respectively). The frequency of relapses and incidence of infections also was comparable. FSGS patients in the MMF group achieved remission faster and received a lower cumulative steroid dose.
“On the basis of this pilot study,” the authors wrote, “we can conclude that in the short term, MMF is as effective as a first-line agent as conventional forms of therapy in the management of adults with nephrotic syndrome due to FSGS and MN and is well tolerated.”